Cyclic thrombospondin-1 mimetics: Grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration

Bioscience Reports

Volumn 35, Issue 6, 2015, Pages

  Chan, Lai Yue ^a   Craik, David J ^a   Daly, Norelle L ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Angiogenesis inhibitors; Endothelial cells; Non toxic; Peptide; Stable; Thrombospondin 1

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLIC THROMBOSPONDIN 1 MIMETIC; CYCLOPEPTIDE; DISULFIDE; HEPTAPEPTIDE; MELITTIN; MOMORDICA COCHINCHINENSIS TRYPSIN INHIBITOR II; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PEPTIDE; SUNFLOWER TRYPSIN INHIBITOR; THROMBOSPONDIN; THROMBOSPONDIN 1; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; CYCLOTIDE; PEPTIDE FRAGMENT; SFTI-1 PEPTIDE, SUNFLOWER; TRYPSIN INHIBITOR MCOTI-II;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL; CAPILLARY ENDOTHELIAL CELL; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTATIC MELANOMA; NUTRIENT SUPPLY; OXYGENATION; PEPTIDE SYNTHESIS; TUMOR VASCULARIZATION; BIOMIMETICS; CELL MOTION; CHEMISTRY; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES; SYNTHESIS;

ANGIOGENESIS INHIBITORS; BIOMIMETICS; CELL MOVEMENT; CELL PROLIFERATION; CYCLOTIDES; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; THROMBOSPONDIN 1;

EID: 84956889439     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20150210     Document Type: Article

References (61)

1. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674 CrossRef PubMed
2. Saaristo, A., Karpanen, T. and Alitalo, K. (2000) Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19, 6122-6129 CrossRef PubMed
3. Ferrara, N. (2009) Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 29, 789-791 CrossRef PubMed
4. Abdollahi, A. and Folkman, J. (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Update 13, 16-28 CrossRef
5. Ribatti, D. and Crivellato, E. (2012) Sprouting angiogenesis", a reappraisal. Dev. Biol. 372, 157-165 CrossRef PubMed
6. Folkman, J. (2007) Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 CrossRef PubMed
7. Good, D.J., Polverini, P.J., Rastinejad, F., Le Beau, M.M., Lemons, R.S., Frazier, W.A. and Bouck, N.P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U.S.A. 87, 6624-6628 CrossRef PubMed
8. Henkin, J. and Volpert, O.V. (2011) Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin. Ther. Targets 15, 1369-1386 CrossRef PubMed
9. Tolsma, S.S., Volpert, O.V., Good, D.J., Frazier, W.A., Polverini, P.J. and Bouck, N. (1993) Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122, 497-511 CrossRef PubMed
10. Lawler, P.R. and Lawler, J. (2012) Molecular basis for the regulation of angiogenesis by thrombospondin-1 and-2. Cold Spring Harb. Perspect. Med. 2, a006627 CrossRef PubMed
11. Lopez-Dee, Z., Pidcock, K. and Gutierrez, L.S. (2011) Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm. 2011, 296069 PubMed
12. Dawson, D.W., Pearce, S.F., Zhong, R., Silverstein, R.L., Frazier, W.A. and Bouck, N.P. (1997) CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717 CrossRef PubMed
13. Dawson, D.W., Volpert, O.V., Pearce, S.F., Schneider, A.J., Silverstein, R.L., Henkin, J. and Bouck, N.P. (1999) Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 55, 332-338 PubMed
14. Haviv, F., Bradley, M.F., Kalvin, D.M., Schneider, A.J., Davidson, D.J., Majest, S.M., McKay, L.M., Haskell, C.J., Bell, R.L., Nguyen, B. et al. (2005) Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J. Med. Chem. 48, 2838-2846 CrossRef PubMed
15. Chen, H., Herndon, M.E. and Lawler, J. (2000) The cell biology of thrombospondin-1. Matrix Biol. 19, 597-614 CrossRef PubMed
16. Febbraio, M., Hajjar, D.P. and Silverstein, R.L. (2001) CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest. 108, 785-791 CrossRef PubMed
17. Silverstein, R.L. and Febbraio, M. (2009) CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci. Signal. 2, re3 CrossRef PubMed
18. Markovic, S.N., Suman, V.J., Rao, R.A., Ingle, J.N., Kaur, J.S., Erickson, L.A., Pitot, H.C., Croghan, G.A., McWilliams, R.R., Merchan, J. et al. (2007) A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am. J. Clin. Oncol. 30, 303-309 CrossRef PubMed
19. Craik, D.J., Daly, N.L., Bond, T. and Waine, C. (1999) Plant cyclotides, A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J. Mol. Biol. 294, 1327-1336 CrossRef PubMed
20. Poth, A.G., Chan, L.Y. and Craik, D.J. (2013) Cyclotides as grafting frameworks for protein engineering and drug design applications. Biopolymers 100, 480-491 CrossRef PubMed
21. Craik, D.J., Fairlie, D.P., Liras, S. and Price, D. (2013) The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136-147 CrossRef PubMed
22. Hernandez, J.F., Gagnon, J., Chiche, L., Nguyen, T.M., Andrieu, J.P., Heitz, A., Trinh Hong, T., Pham, T.T. and Le Nguyen, D. (2000) Squash trypsin inhibitors from Momordica cochinchinensis exhibit an atypical macrocyclic structure. Biochemistry 39, 5722-5730 CrossRef PubMed
23. Luckett, S., Garcia, R.S., Barker, J.J., Konarev, A.V., Shewry, P.R., Clarke, A.R. and Brady, R.L. (1999) High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J. Mol. Biol. 290, 525-533 CrossRef PubMed
24. Quimbar, P., Malik, U., Sommerhoff, C.P., Kaas, Q., Chan, L.Y., Huang, Y.H., Grundhuber, M., Dunse, K., Craik, D.J., Anderson, M.A. et al. (2013) High-affinity cyclic peptide matriptase inhibitors. J. Biol. Chem. 288, 13885-13896 CrossRef PubMed
25. Colgrave, M.L. and Craik, D.J. (2004) Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry 43, 5965-5975 CrossRef PubMed
26. Daly, N.L., Chen, Y.K., Foley, F.M., Bansal, P.S., Bharathi, R., Clark, R.J., Sommerhoff, C.P. and Craik, D.J. (2006) The absolute structural requirement for a proline in the P3'-position of Bowman-Birk protease inhibitors is surmounted in the minimized SFTI-1 scaffold. J. Biol. Chem. 281, 23668-23675 CrossRef PubMed
27. Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A.Y., Neamati, N., Shekhtman, A. and Camarero, J.A. (2013) In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. J. Am. Chem. Soc. 135, 11623-11633 CrossRef PubMed
28. Aboye, T.L., Ha, H., Majumder, S., Christ, F., Debyser, Z., Shekhtman, A., Neamati, N. and Camarero, J.A. (2012) Design of a novel cyclotide-based CXCR4 antagonist with anti-human immunodeficiency virus (HIV)-1 activity. J. Med. Chem. 55, 10729-10734 CrossRef PubMed
29. Chan, L.Y., Gunasekera, S., Henriques, S.T., Worth, N.F., Le, S.J., Clark, R.J., Campbell, J.H., Craik, D.J. and Daly, N.L. (2011) Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds. Blood 118, 6709-6717 CrossRef PubMed
30. Thongyoo, P., Bonomelli, C., Leatherbarrow, R.J. and Tate, E.W. (2009) Potent inhibitors of beta-tryptase and human leukocyte elastase based on the MCoTI-II scaffold. J. Med. Chem. 52, 6197-6200 CrossRef PubMed
31. Thongyoo, P., Roque-Rosell, N., Leatherbarrow, R.J. and Tate, EW. (2008) Chemical and biomimetic total syntheses of natural and engineered MCoTI cyclotides. Org. Biomol. Chem. 6, 1462-1470 CrossRef PubMed
32. Sommerhoff, C.P., Avrutina, O., Schmoldt, H.U., Gabrijelcic-Geiger, D., Diederichsen, U. and Kolmar, H. (2010) Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta. J. Mol. Biol. 395, 167-175 CrossRef PubMed
33. Dawson, P.E., Muir, T.W., Clark-Lewis, I. and Kent, S.B. (1994) Synthesis of proteins by native chemical ligation. Science 266, 776-779 CrossRef PubMed
34. Chan, L.Y., Wang, C.K., Major, J.M., Greenwood, K.P., Lewis, R.J., Craik, D.J. and Daly, N.L. (2009) Isolation and characterization of peptides from Momordica cochinchinensis seeds. J. Nat. Prod. 72, 1453-1458 CrossRef PubMed
35. Short, S.M., Derrien, A., Narsimhan, R.P., Lawler, J., Ingber, D.E. and Zetter, B.R. (2005) Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J. Cell Biol. 168, 643-653 CrossRef PubMed
36. Getz, J.A., Cheneval, O., Craik, D.J. and Daugherty, P.S. (2013) Design of a cyclotide antagonist of neuropilin-1 and-2 that potently inhibits endothelial cell migration. ACS Chem. Biol. 8, 1147-1154 CrossRef PubMed
37. Bianco, C., Strizzi, L., Ebert, A., Chang, C., Rehman, A., Normanno, N., Guedez, L., Salloum, R., Ginsburg, E., Sun, Y. et al. (2005) Role of human cripto-1 in tumor angiogenesis. J. Natl. Cancer Inst. 97, 132-141 CrossRef PubMed
38. Kramer, N., Walzl, A., Unger, C., Rosner, M., Krupitza, G., Hengstschlager, M. and Dolznig, H. (2013) In vitro cell migration and invasion assays. Mutat. Res. 752, 10-24 CrossRef PubMed
39. Magnussen, A.L., Rennel, E.S., Hua, J., Bevan, H.S., Beazley Long, N., Lehrling, C., Gammons, M., Floege, J., Harper, S.J., Agostini, H.T. et al. (2010) VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest. Ophthalmol. Vis. Sci. 51, 4273-4281 CrossRef PubMed
40. Chao, W.R., Amin, K., Shi, Y., Hobbs, P., Tanabe, M., Tanga, M., Jong, L., Collins, N., Peters, R., Laderoute, K. et al. (2011) SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo. Angiogenesis 14, 1-16 CrossRef PubMed
41. Hua, J., Spee, C., Kase, S., Rennel, E.S., Magnussen, A.L., Qiu, Y., Varey, A., Dhayade, S., Churchill, A.J., Harper, S.J. et al. (2010) Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 51, 4282-4288 CrossRef PubMed
42. Vranken, W.F., Boucher, W., Stevens, T.J., Fogh, R.H., Pajon, A., Llinas, M., Ulrich, E.L., Markley, J.L., Ionides, J. and Laue, E.D. (2005) The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687-696 CrossRef PubMed
43. Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C.A., Amini, B., Andersen, E., Andersson, A.C., Angelidou, P., Asplund, A., Asplund, C. et al. (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteomics 4, 1920-1932 CrossRef PubMed
44. Petryszak, R., Burdett, T., Fiorelli, B., Fonseca, N.A., Gonzalez-Porta, M., Hastings, E., Huber, W., Jupp, S., Keays, M., Kryvych, N. et al. (2014) Expression Atlas update-a database of gene and transcript expression from microarray-and sequencing-based functional genomics experiments. Nucleic Acids Res. 42, D926-D932 CrossRef PubMed
45. Kimura, R.H., Teed, R., Hackel, B.J., Pysz, M.A., Chuang, C.Z., Sathirachinda, A., Willmann, J.K. and Gambhir, S.S. (2012) Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin. Cancer Res. 18, 839-849 CrossRef PubMed
46. Patch, J.A. and Barron, A.E. (2002) Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers. Curr. Opin. Chem. Biol. 6, 872-877 CrossRef PubMed
47. Clark, R.J., Fischer, H., Dempster, L., Daly, N.L., Rosengren, K.J., Nevin, S.T., Meunier, F.A., Adams, D.J. and Craik, D.J. (2005) Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. Proc. Natl. Acad. Sci. U.S.A. 102, 13767-13772 CrossRef PubMed
48. Chatterjee, J., Gilon, C., Hoffman, A. and Kessler, H. (2008) N-methylation of peptides: a new perspective in medicinal chemistry. Acc. Chem. Res. 41, 1331-1342 CrossRef PubMed
49. Noel, A., Maillard, C., Rocks, N., Jost, M., Chabottaux, V., Sounni, N.E., Maquoi, E., Cataldo, D. and Foidart, J.M. (2004) Membrane associated proteases and their inhibitors in tumour angiogenesis. J. Clin. Pathol. 57, 577-584 CrossRef PubMed
50. Bauvois, B. (2004) Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene 23, 317-329 CrossRef PubMed
51. LeBeau, A.M., Lee, M., Murphy, S.T., Hann, B.C., Warren, R.S., Delos Santos, R., Kurhanewicz, J., Hanash, S.M., VanBrocklin, H.F. and Craik, C.S. (2013) Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc. Natl. Acad. Sci. U.S.A. 110, 93-98 CrossRef PubMed
52. Oberst, M.D., Singh, B., Ozdemirli, M., Dickson, R.B., Johnson, M.D. and Lin, C.Y. (2003) Characterization of matriptase expression in normal human tissues. J. Histochem. Cytochem. 51, 1017-1025 CrossRef PubMed
53. Gray, K., Elghadban, S., Thongyoo, P., Owen, K.A., Szabo, R., Bugge, T.H., Tate, E.W., Leatherbarrow, R.J. and Ellis, V. (2014) Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II. Thromb. Haemost. 112, 402-411 CrossRef PubMed
54. Muller, P.Y. and Milton, M.N. (2012) The determination and interpretation of the therapeutic index in drug development. Nat. Rev. Drug Discov. 11, 751-761 CrossRef PubMed
55. Eskens, F.A. and Verweij, J. (2006) The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur. J. Cancer 42, 3127-3139 CrossRef PubMed
56. Klenotic, P.A., Page, R.C., Li, W., Amick, J., Misra, S. and Silverstein, R.L. (2013) Molecular basis of antiangiogenic thrombospondin-1 type 1 repeat domain interactions with CD36. Arterioscler. Thromb. Vasc. Biol. 33, 1655-1662 CrossRef PubMed
57. Swerlick, R.A., Lee, K.H., Wick, T.M. and Lawley, T.J. (1992) Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J. Immunol. 148, 78-83 PubMed
58. Petzelbauer, P., Bender, J.R., Wilson, J. and Pober, J.S. (1993) Heterogeneity of dermal microvascular endothelial cell antigen expression and cytokine responsiveness in situ and in cell culture. J. Immunol. 151, 5062-5072 PubMed
59. Daly, N.L., Thorstholm, L., Greenwood, K.P., King, G.J., Rosengren, K.J., Heras, B., Martin, J.L. and Craik, D.J. (2013) Structural insights into the role of the cyclic backbone in a squash trypsin inhibitor. J. Biol. Chem. 288, 36141-36148 CrossRef PubMed
60. D'Souza, C., Henriques, S.T., Wang, C.K. and Craik, D.J. (2014) Structural parameters modulating the cellular uptake of disulfide-rich cyclic cell-penetrating peptides: MCoTI-II and SFTI-1. Eur. J. Med. Chem. 88, 10-18 CrossRef PubMed
61. Koradi, R., Billeter, M. and Wuthrich, K. (1996) MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 51-55 CrossRef PubMed